Abstract
Modern biology has not transformed the landscape of cardiac insufficiency, CI, but to some degree in this rather complex domain, it has permitted us to actually distinguish between what is and what is not a physiological process of adaptation of a diseased organ. This distinction is not one of rhetorical importance. It facilitates the dialogue between clinicians and fundamentalists. Above all it permits us to look at therapy from a different perspective and hopefully at the conception of new drugs. From this progress has emerged evidence that the structure of inotropic targets, myocardial contractile cells, are already profoundly modified at the moment when the first peripherial clinical signs that define CI arise. In other terms, inotropic agents, more or less those drugs having a myocardial activity, are advisably the keys to use in conceptualizing function because the lock in which they must play is modified [1].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Reference
Swynghedauw B. Cardiac hypertrophy and failure. INSERM J 1990; Libbey, Paris, London.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Swynghedauw, B. (1993). Heart Failure: A Disease of Adaptation. In: Ostadal, B., Dhalla, N.S. (eds) Heart Function in Health and Disease. Developments in Cardiovascular Medicine, vol 140. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3090-9_21
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3090-9_21
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6350-7
Online ISBN: 978-1-4615-3090-9
eBook Packages: Springer Book Archive